Segall Bryant & Hamill’s iShares Biotechnology ETF IBB Stock Holding History

Segall Bryant & Hamill’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,747	Closed	-$603K	–	593
2023 Q2	$603K	Hold	4,747	–	–	0.01%	545
2023 Q1	$613K	Sell	4,747 -275	-5%	-$36K	0.01%	540
2022 Q4	$659K	Sell	5,022 -36	-0.7%	-$4.65K	0.01%	534
2022 Q3	$594K	Sell	5,058 -300	-6%	-$37.3K	0.01%	555
2022 Q2	$630K	Sell	5,358 -245	-4%	-$29.1K	0.01%	553
2022 Q1	$734K	Buy	+5,603	New	+$730K	0.01%	553
2021 Q4	–	Sell	-5,712	Closed	-$926K	–	651
2021 Q3	$926K	Sell	5,712 -237	-4%	-$39.9K	0.01%	542
2021 Q2	$975K	Buy	5,949 +1,750	+42%	+$270K	0.01%	522
2021 Q1	$634K	Sell	4,199 -50	-1%	-$7.94K	0.01%	609
2020 Q4	$643K	Hold	4,249	–	–	0.01%	531
2020 Q3	$575K	Sell	4,249 -185	-4%	-$25.1K	0.01%	524
2020 Q2	$608K	Hold	4,434	–	–	0.01%	549
2020 Q1	$473K	Hold	4,434	–	–	0.01%	602
2019 Q4	$530K	Hold	4,434	–	–	0.01%	646
2019 Q3	$442K	Buy	4,434 +50	+1%	+$5.23K	0.01%	669
2019 Q2	$477K	Buy	4,384 +12	+0.3%	+$1.28K	0.01%	667
2019 Q1	$487K	Sell	4,372 -714	-14%	-$78.3K	0.01%	664
2018 Q4	$490K	Hold	5,086	–	–	0.01%	647
2018 Q3	$620K	Sell	5,086 -200	-4%	-$23.6K	0.01%	631
2018 Q2	$581K	Buy	5,286 +516	+11%	+$55.2K	0.01%	645
2018 Q1	$509K	Hold	4,770	–	–	0.01%	432
2017 Q4	$509K	Hold	4,770	–	–	0.01%	418
2017 Q3	$530K	Hold	4,770	–	–	0.01%	420
2017 Q2	$493K	Buy	4,770 +1,740	+57%	+$171K	0.01%	432
2017 Q1	$296K	Hold	3,030	–	–	0.01%	478
2016 Q4	$268K	Hold	3,030	–	–	0.01%	487
2016 Q3	$292K	Sell	3,030 -576	-16%	-$54.8K	0.01%	479
2016 Q2	$309K	Hold	3,606	–	–	0.01%	477
2016 Q1	$313K	Hold	3,606	–	–	0.01%	474
2015 Q4	$407K	Hold	3,606	–	–	0.01%	438
2015 Q3	$365K	Hold	3,606	–	–	0.01%	457
2015 Q2	$444K	Hold	3,606	–	–	0.01%	437
2015 Q1	$413K	Hold	3,606	–	–	0.01%	448
2014 Q4	$365K	Hold	3,606	–	–	0.01%	462
2014 Q3	$329K	Hold	3,606	–	–	0.01%	479
2014 Q2	$309K	Hold	3,606	–	–	0.01%	494
2014 Q1	$284K	Buy	3,606 +510	+16%	+$42.5K	0.01%	523
2013 Q4	$234K	Hold	3,096	–	–	0.01%	546
2013 Q3	$216K	Buy	+3,096	New	+$203K	0.01%	544

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Segall Bryant & Hamill's IBB Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of iShares Biotechnology ETF (IBB) in Q3 2023, closing a stake of 4,747 shares — an estimated $603K sold.

Segall Bryant & Hamill first reported a position in IBB in Q3 2013 and held it in 39 quarters. The position peaked at $975K in Q2 2021. 833 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Segall Bryant & Hamill reported no remaining iShares Biotechnology ETF position as of Q3 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 4,747 iShares Biotechnology ETF shares in Q3 2023, an estimated $603K.
Segall Bryant & Hamill first reported a position in iShares Biotechnology ETF in Q3 2013 and held it in 39 quarters.
Segall Bryant & Hamill's iShares Biotechnology ETF position peaked at $975K in Q2 2021.
833 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.